Journal article
Closed-Loop Insulin Delivery Effects on Glycemia during Sleep and Sleep Quality in Older Adults with Type 1 Diabetes: Results from the ORACL Trial
A Chakrabarti, S Trawley, E Kubilay, A Mohammad Alipoor, S Vogrin, S Fourlanos, MH Lee, DN O'Neal, NA O'Regan, V Sundararajan, GM Ward, RJ Macisaac, PG Colman, SA McAuley
Diabetes Technology and Therapeutics | MARY ANN LIEBERT, INC | Published : 2022
Abstract
Sleep-related effects of closed-loop therapy among older adults with type 1 diabetes have not been well established. In the OldeR Adult Closed-Loop (ORACL) randomized, crossover trial of first-generation closed-loop therapy (MiniMed 670G), participants wore actigraphy and completed sleep diaries for 14-day periods at stage end. During objectively measured sleep (actigraphy) with closed-loop versus sensor-augmented pump therapy, glucose time-in-range 70-180 mg/dL (3.9-10.0 mmol/L) was greater (90.3% vs. 78.7%, respectively; difference 8.2 percentage points [95% confidence interval {CI} 1.5 to 13.0]; P = 0.008), and there were fewer sensor hypoglycemia episodes (18 vs. 43, respectively; incide..
View full abstractRelated Projects (1)
Grants
Awarded by Eli Lilly and Company
Funding Acknowledgements
The ORACL trial was funded by JDRF (3-SRA-2018-667-M-R), the Diabetes Australia Research Program and St Vincents Hospital (Melbourne) Research Endowment Fund. Medtronic supplied discounted insulin pumps and glucose monitoring devices for the study. S.A.M. is supported by a JDRF Research Award. M.H.L. is supported by a National Health and Medical Research Council (NHMRC)postgraduate scholarship, co-funded by Diabetes Australia. The funders of this study had no role in trial design, data collection, data analysis, data interpretation, or writing of the report